Overactivation of cannabinoid receptor type 1 in rostral ventrolateral medulla promotes cardiovascular responses in spontaneously hypertensive rats

Journal of Hypertension

Volumn 35, Issue 3, 2017, Pages 538-545

  Wang, Tao ^a   Li, Guo Qi ^a,b   Zhang, Hui Ping ^b   Zhang, Yi ^a,b   Li, Qian ^a,b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

Cannabinoid receptor; Hypertension; Rostral ventrolateral medulla; Spontaneously hypertensive rats; Sympathoexcitation

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; BETA ARRESTIN 2; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; ARACHIDONIC ACID DERIVATIVE; ARACHIDONYL-2-CHLOROETHYLAMIDE; ARRB2 PROTEIN, RAT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; GENE OVEREXPRESSION; HEART RATE; JUVENILE ANIMAL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ROSTRAL VENTROLATERAL MEDULLA; SPONTANEOUSLY HYPERTENSIVE RAT; SURFACE PROPERTY; WILD TYPE; ADRENERGIC SYSTEM; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HYPERTENSION; INNERVATION; KIDNEY; MEDULLA OBLONGATA; METABOLISM; MICROINJECTION; PATHOPHYSIOLOGY;

ANIMALS; ARACHIDONIC ACIDS; BETA-ARRESTIN 2; BLOOD PRESSURE; HEART RATE; HYPERTENSION; KIDNEY; MALE; MEDULLA OBLONGATA; MICROINJECTIONS; PIPERIDINES; PYRAZOLES; RATS; RATS, INBRED SHR; RECEPTOR, CANNABINOID, CB1; SYMPATHETIC NERVOUS SYSTEM;

EID: 84995777962     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001179     Document Type: Article

References (37)

1. Aronow WS. Treatment of systemic hypertension. Am J Cardiovasc Dis 2012; 2:160-170.
2. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003; 139:761-776.
3. Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26:381-391.
4. Luft FC. Molecular genetics of human hypertension. Curr Opin Nephrol Hypertens 2000; 9:259-266.
5. Victor RG, Shafiq MM. Sympathetic neural mechanisms in human hypertension. Curr Hypertens Rep 2008; 10:241-247.
6. Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens Suppl 1996; 14:S159-S165.
7. Sugiyama Y, Suzuki T, Yates BJ. Role of the rostral ventrolateral medulla (RVLM) in the patterning of vestibular system influences on sympathetic nervous system outflow to the upper and lower body. Exp Brain Res 2011; 210:515-527.
8. Carlson SH, Wyss JM. Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action. Curr Hypertens Rep 2008; 10:233-240.
9. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006; 7:335-346.
10. Pilowsky PM, Goodchild AK. Baroreceptor reflex pathways and neurotransmitters: 10 years on. J Hypertens 2002; 20:1675-1688.
11. Pilowsky PM, Jiang C, Lipski J. An intracellular study of respiratory neurons in the rostral ventrolateral medulla of the rat and their relationship to catecholamine-containing neurons. J Comp Neurol 1990; 301:604-617.
12. Sun QJ, Goodchild AK, Chalmers JP, Pilowsky PM. The pre-Botzinger complex and phase-spanning neurons in the adult rat. Brain Res 1998; 809:204-213.
13. Moraes DJ, Machado BH, Paton JF. Specific respiratory neuron types have increased excitability that drive presympathetic neurones in neurogenic hypertension. Hypertension 2014; 63:1309-1318.
14. Padley JR, Li Q, Pilowsky PM, Goodchild AK. Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats. Br J Pharmacol 2003; 140:384-394.
15. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, et al. Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 1999; 19:3773-3780.
16. Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK. Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 S/S mice. Behav Pharmacol 2008; 19:298-307.
17. Paxinos G, Watson C. The rat brain in stereotaxic coordinates, 4th ed. San Diego: Academic Press; 1998.
18. Dickhout JG, Lee RM. Blood pressure and heart rate development in young spontaneously hypertensive rats. Am J Physiol 1998; 274 (3 Pt 2):H794-H800.
19. Li P, Gong JX, Sun W, Zhou B, Kong XQ. Hexamethonium attenuates sympathetic activity and blood pressure in spontaneously hypertensive rats. Mol Med Rep 2015; 12:7116-7122.
20. Francisco LL, Sawin LL, Di Bona GF. Renal sympathetic nerve activity and the exaggerated natriuresis of the spontaneous hypertensive rat. Hypertension 1981; 3:134-138.
21. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110:1996-2002.
22. Kouznetsova M, Kelley B, Shen M, Thayer SA. Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Mol Pharmacol 2002; 61:477-485.
23. Daigle TL, Kwok ML, Mackie K. Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism. J Neurochem 2008; 106:70-82.
24. Daigle TL, Kearn CS, Mackie K. Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology 2008; 54:36-44.
25. Stornetta RL, Sevigny CP, Guyenet PG. Vesicular glutamate transporter DNPI/VGLUT2 mRNA is present in C1 and several other groups of brainstem catecholaminergic neurons. J Comp Neurol 2002; 444:191-206.
26. Stornetta RL, Sevigny CP, Schreihofer AM, Rosin DL, Guyenet PG. Vesicular glutamate transporter DNPI/VGLUT2 is expressed by both C1 adrenergic and nonaminergic presympathetic vasomotor neurons of the rat medulla. J Comp Neurol 2002; 444:207-220.
27. Stornetta RL. Neurochemistry of bulbospinal presympathetic neurons of the medulla oblongata. J Chem Neuroanat 2009; 38:222-230.
28. Jansen AS, Wessendorf MW, Loewy AD. Transneuronal labeling of CNS neuropeptide and monoamine neurons after pseudorabies virus injections into the stellate ganglion. Brain Res 1995; 683:1-24.
29. Agassandian K, Shan Z, Raizada M, Sved AF, Card JP. C1 catecholamine neurons form local circuit synaptic connections within the rostroventrolateral medulla of rat. Neuroscience 2012; 227:247-259.
30. Card JP, Sved JC, Craig B, Raizada M, Vazquez J, Sved AF. Efferent projections of rat rostroventrolateral medulla C1 catecholamine neurons: Implications for the central control of cardiovascular regulation. J Comp Neurol 2006; 499:840-859.
31. De Puy SD, Stornetta RL, Bochorishvili G, Deisseroth K, Witten I, Coates M, et al. Glutamatergic neurotransmission between the C1 neurons and the parasympathetic preganglionic neurons of the dorsal motor nucleus of the vagus. J Neurosci 2013; 33:1486-1497.
32. Park JB, Jo JY, Zheng H, Patel KP, Stern JE. Regulation of tonic GABA inhibitory function, presympathetic neuronal activity and sympathetic outflow from the paraventricular nucleus by astroglial GABA transporters. J Physiol 2009; 587 (Pt 19):4645-4660.
33. Lewis DI, Coote JH. Baroreceptor-induced inhibition of sympathetic neurons by GABA acting at a spinal site. Am J Physiol 1996; 270 (6 Pt 2):H1885-H1892.
34. Ibrahim BM, Abdel-Rahman AA. Role of brainstem GABAergic signaling in central cannabinoid receptor evoked sympathoexcitation and pressor responses in conscious rats. Brain Res 2011; 1414:1-9.
35. Pacher P, Batkai S, Kunos G. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 2005; 48:1130-1138.
36. Niederhoffer N, Szabo B. Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J Pharmacol Exp Ther 2000; 294:707-713.
37. Pfitzer T, Niederhoffer N, Szabo B. Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats. Br J Pharmacol 2004; 142:943-952.